Tackling the Rise of Drug-Resistant Gonorrhea

Partnership to develop new drug

Global Antibiotic Research and Development Partnership (GARDP), Entasis and Drugs for Neglected Diseases initiative (DNDi), July 2017

4 pp. 971 kB
https://www.gardp.org/wp-content/uploads/2017/07/Gonorrhea_Brief_July_2017.pdf

The spread and incidence of drug-resistant gonorrhea is rapidly outpacing the development of new drugs; without action the world faces a nightmare scenario of untreatable gonorrhea. A new partnership agreement between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics to develop a new drug, zoliflodacin, specifically to treat gonorrhea, hopes to provide a solution. GARDP is a joint initiative of the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi), which provides GARDP’s governance.

(Visited 5 times, 1 visits today)
This entry was posted in Essential Medicines, General, Sexual & Reproductive Health. Bookmark the permalink.